Application of novel quantitative techniques for fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer

被引:11
|
作者
Wang, Duo [1 ,2 ]
Koh, Eng-Siew [1 ,5 ,6 ]
Descallar, Joseph [1 ,5 ]
Pramana, Ariyanto [7 ]
Vinod, Shalini K. [6 ,8 ,9 ]
Shon, Ivan Ho [1 ,3 ,4 ]
机构
[1] Univ New South Wales, Sydney, NSW, Australia
[2] Concord Repatriat Gen Hosp, Sydney, NSW, Australia
[3] Prince Wales Hosp, Dept Nucl Med, Sydney, NSW, Australia
[4] Prince Wales Hosp, PET, Sydney, NSW, Australia
[5] Ingham Inst Appl Med Res, Sydney, NSW, Australia
[6] Liverpool & Macarthur Canc Therapy Ctr, Sydney, NSW, Australia
[7] St George Canc Care Ctr, Sydney, NSW, Australia
[8] Univ Western Sydney, Sydney, NSW, Australia
[9] UNSW, Southwestern Sydney Clin Sch, Sydney, NSW, Australia
关键词
metabolic tumor volume; non-small-cell lung cancer; prognosis; standard uptake value; total lesional glycolysis; TOTAL LESION GLYCOLYSIS; METABOLIC TUMOR VOLUME; STANDARDIZED UPTAKE VALUE; OPEN-SOURCE SOFTWARE; PROGNOSTIC VALUE; F-18-FDG PET/CT; DISEASE PROGRESSION; STAGING SYSTEM; FDG PET/CT; RADIOTHERAPY;
D O I
10.1111/ajco.12587
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: Flurodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) is routinely used in non-small-cell lung cancer. This study aims to assess the prognostic value of quantitative FDG-PET/CT parameters including standard uptake value (SUV), metabolic tumor volume (MTV) and total lesional glycolysis (TLG) in non-small-cell lung cancer. Methods: A retrospective review of 92 nonsurgical patients with pathologically confirmed stage I-III non-small-cell lung cancers treated with radical dose radiotherapy (>= 50 Gy) was conducted. Metabolically active tumor regions on FDG-PET/CT scans were contoured manually. SUV, MTV and TLG were calculated for primary, nodal and whole-body disease. Univariate and multivariate (adjusting for age, sex, disease stage and primary tumor size in centimeters) Cox regression modeling were performed to assess the association between these parameters and both overall and progression-free survival (PFS). Results: On univariate analysis, overall survival (OS) was significantly associated with primary MTV (P = 0.03), whole-body MTV (P = 0.02), whole-body maximum SUV (P = 0.05) and whole-body TLG (P = 0.03). PFS was significantly associated with primary MTV (P = 0.01), primary TLG (P = 0.04), whole-body MTV (P < 0.01) and whole-body TLG (P = 0.01). On multivariate analysis, OS was significantly associated with whole-body MTV (P = 0.05). PFS was significantly associated with whole-body MTV (P = 0.02) and whole-body TLG (P = 0.05). Conclusions: Whole-body MTV was significantly associated with overall and PFS, and whole-body TLG was significantly associated with PFS on multivariate analysis. These two parameters may be significant prognostic factors independent of other factors such as stage. SUV was not significantly associated with survival on multivariate analysis.
引用
收藏
页码:349 / 358
页数:10
相关论文
共 50 条
  • [31] The Role of Positron Emission Tomography-Computed Tomography in the Workup of Non-Small Cell Lung Cancer
    Walter, Martin A.
    JAMA NETWORK OPEN, 2019, 2 (11)
  • [32] Integrated positron emission tomography/computed tomography in patients with non-small cell lung cancer - Normal variants and pitfalls
    Truong, MT
    Erasmus, JJ
    Macapinlac, HA
    Marom, EM
    Mawlawi, O
    Gladish, GW
    Sabloff, BS
    Bruzzi, JE
    Munden, RF
    JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2005, 29 (02) : 205 - 209
  • [33] The Role Of Positron Emission Tomography - Computed Tomography (PET/CT) In The Prognosis Of Patients With Non Small Cell Lung Cancer (NSCLC)
    Tesfaye, A.
    Mozayen, M.
    Sarangi, M.
    Nagpal, S.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S295 - S295
  • [34] Lung cancer and positron emission tomography with fluorodeoxyglucose
    Marom, EM
    Erasmus, JJ
    Patz, EF
    LUNG CANCER, 2000, 28 (03) : 187 - 202
  • [35] Predictive Value of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for Assessment of Occult Lymph Node Metastasis in Non-Small Cell Lung Cancer
    Seol, Hee Yun
    Kim, Yun Seong
    Kim, Seong-Jang
    ONCOLOGY, 2021, 99 (02) : 96 - 104
  • [36] Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: A review
    Pillot, Giancarlo
    Siegel, Barry A.
    Govindan, Ramaswamy
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (02) : 152 - 159
  • [37] Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer
    Taylor, Matthew D.
    Smith, Philip W.
    Brix, William K.
    Wick, Mark R.
    Theodosakis, Nicholas
    Swenson, Brian R.
    Kozower, Benjamin D.
    Lau, Christine L.
    Jones, David R.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2009, 137 (01): : 43 - 48
  • [38] Is there a role for positron emission tomography/computed tomography in the staging of small-cell lung cancer?
    Truong, Mylene T.
    Marom, Edith M.
    CLINICAL LUNG CANCER, 2008, 9 (01) : 8 - 8
  • [39] Detection of lung cancer in patients with pneumoconiosis by fluorodeoxyglucose-positron emission tomography/computed tomography: four cases
    Yu, Hua
    Zhang, Hua
    Wang, Yanli
    Cui, Xinjian
    Han, Jiankui
    CLINICAL IMAGING, 2013, 37 (04) : 769 - 771
  • [40] Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation
    Klopp, Ann Hoge
    Chang, Joe Y.
    Tucker, Susan L.
    Sulman, Erik P.
    Balter, Peter A.
    HelenLiu, H.
    Bucci, M. Kara
    Macapinlac, Homer A.
    Komaki, Ritsuko
    Cox, James D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (05): : 1409 - 1416